| # | Title | Journal | Year | Citations |
|---|
| 1 | Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2011 | 21 |
| 2 | HER2 Overexpression/Amplification and Trastuzumab Treatment in Advanced Ovarian Cancer: A GINECO Phase II Study | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 14 |
| 3 | Is Serum Albumin an Independent Predictor of Survival in Ovarian Cancer? | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 11 |
| 4 | The 45th Annual Meeting of the American Society of Clinical Oncology Orlando, FL; May 29 – June 2, 2009 | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 10 |
| 5 | Platelet-Derived Growth Factor Pathway Inhibitors in Ovarian Cancer | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 7 |
| 6 | Successful Treatment of Metastatic Squamous Cell Carcinoma of the Ovary Arising Within a Mature Cystic Teratoma | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2011 | 7 |
| 7 | PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2011 | 6 |
| 8 | Making of a Phase III Study in Recurrent Ovarian Cancer: The Odyssey of GOG 213 | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 5 |
| 9 | HER2 Overexpression/Amplification and Trastuzumab Treatment in Advanced Ovarian Cancer: A GINECO Phase II Study | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 5 |
| 10 | PRO: Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 5 |
| 11 | A Phase I/II Study of Lapatinib Plus Carboplatin and Paclitaxel in Relapsed Ovarian and Breast Cancer | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 5 |
| 12 | DNA Repair–Based Mechanisms of Platinum Resistance in Epithelial Ovarian Cancer: From Bench to Bedside | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2010 | 5 |
| 13 | Lysophosphatidic Acid in Patients With Ovarian Cancer | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2010 | 5 |
| 14 | Preoperative Serum Levels of Epidermal Growth Factor Receptor, HER2, and Vascular Endothelial Growth Factor in Malignant and Benign Ovarian Tumors | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 4 |
| 15 | Intraperitoneal Chemotherapy for Stage III Ovarian Cancer Using the Gynecologic Oncology Group Protocol 172 Intraperitoneal Regimen: Effect of Supportive Care Using Aprepitant and Pegfilgrastim on Treatment Completion Rate | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 4 |
| 16 | Ovarian Cancer in a Man? | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 4 |
| 17 | Current Challenges and Future Directions in the Management of Ovarian Cancer: Proceedings of the First Global Workshop on Ovarian Cancer | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2010 | 4 |
| 18 | Papillary Thyroid Carcinoma Arising in a Struma Ovarii: A Case Report and Analysis of Cases Reported in the Literature | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2010 | 4 |
| 19 | Optimizing Management of Recurrent Epithelial Ovarian Cancer with Non–Platinum-Based Chemotherapy | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 3 |
| 20 | Use of Docetaxel After Paclitaxel Hypersensitivity Reaction in Epithelial Ovarian and Endometrial Cancer | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 3 |
| 21 | VEGF in the Development of Ovarian Malignancy | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2011 | 3 |
| 22 | The Prognostic Value of Syndecan-1 in Ovarian Cancer Patients with Long-Term Follow up | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2011 | 3 |
| 23 | Results of an Open-Label Study to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Carboplatin-Containing Chemotherapy in Patients with Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Carcinoma (Stage I-IV) or Papillary Serous Cancer of the Uterus | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 2 |
| 24 | PRO: Patients With Metastatic/Recurrent Cervical Cancer Should Be Treated With Cisplatin Plus Paclitaxel | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2010 | 2 |
| 25 | PRO: Systemic Therapy for All Endometrial Cancers Should Be Paclitaxel Plus Carboplatin | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2010 | 2 |
| 26 | Isolated Myeloid Sarcoma of the Vulva | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2011 | 2 |
| 27 | The Efficacy and Toxicity of Bevacizumab in Combination With Gemcitabine in Patients With Recurrent Ovarian Cancer | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2011 | 2 |
| 28 | The Use of Radiofrequency Ablation in Advanced Ovarian Cancer: Resection and Ablation of Liver Metastases | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 1 |
| 29 | Highlights from: The Annual Meeting of the Society of Gynecologic Oncologists; March 9–12, 2008; Tampa, FL | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 1 |
| 30 | PRO: Therapy for a Patient with Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should Be Selected Based on the Result of an In Vitro Chemoresistance Assay | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 1 |
| 31 | PRO: Patients with Recurrent Ovarian Cancer Should Be Treated with Antiangiogenic Agents in Combination with Chemotherapy | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 1 |
| 32 | Trial Design Strategies for Vascular-Targeted Therapy of Patients with Ovarian Cancer | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 1 |
| 33 | Safety of Bevacizumab in Advanced Ovarian and Müllerian Cancers: A Review | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 1 |
| 34 | Phase III Trial of Induction Gemcitabine or Paclitaxel Plus Carboplatin Followed by Elective Paclitaxel Consolidation in Ovarian Cancer: Interim Analysis of Induction Chemotherapy | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 1 |
| 35 | Synchronous Ovarian Metastasis in Apparently Normal Ovaries During Surgery for Gastric and Colorectal Carcinoma: The Role of Routine Ovarian Biopsy | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 1 |
| 36 | A Longitudinal Analysis Investigating the Impact of Improvement in Serum Albumin Scores on Survival in Ovarian Cancer | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 1 |
| 37 | Evaluation of the Significance of CA-125 Levels in Patients With Epithelial Ovarian Cancer in Bihar, India | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 1 |
| 38 | A Rare Case of Primary Ovarian Lymphoma in Patients With Rheumatoid Arthritis: Can We Attribute This to Tumor Necrosis Factor Inhibitors? | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2009 | 1 |
| 39 | Weekly Administration of Paclitaxel and Carboplatin in the Treatment of Advanced Ovarian or Peritoneal Cancers With Poor Performance Status | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2010 | 1 |
| 40 | A Pilot Study of Laparoscopic Extraperitoneal Lymph Node Dissection in Patients With Locally Advanced Cervical Cancer: A Trial Design Report | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2010 | 1 |
| 41 | The Impact of Age on the Treatment and Survival of Ovarian Cancer Patients | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2010 | 1 |
| 42 | The Annual Meeting of the American Society of Clinical Oncology | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2010 | 1 |
| 43 | Luteinized Fibroma of the Ovary With Minor Sex Cord Elements: An Incidental Finding | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2011 | 1 |
| 44 | Clinical Indications for Human Papillomavirus Vaccination | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 0 |
| 45 | Maintenance Therapy in Epithelial Ovarian Cancer: Rationale and Results | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 0 |
| 46 | Erythropoiesis-Stimulating Agents and the Practice of Gynecologic Oncology | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 0 |
| 47 | A Comparison of Reimbursement for Outpatient Intraperitoneal Chemotherapy Versus Intravenous Therapy for Ovarian Cancer | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 0 |
| 48 | Issues in the Design of Ovarian Cancer Trials Evaluating Antineoplastic Agents Not Predicted to Cause Regression of Existing Tumor Masses | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 0 |
| 49 | Bevacizumab in the Management of Epithelial Ovarian Cancer | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 0 |
| 50 | Report on the Gynecologic Oncology Group | Clinical Ovarian Cancer & Other Gynecologic Malignancies | 2008 | 0 |
